SCHEMBL4342184

SCHEMBL4342184

O=[N+]([O-])c1ccc(Sc2ccccc2CNc2ccc(O)c(Cl)c2)cc1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.47
ALDH1A1 P00352 2/20 0.47
PDE7A Q13946 2/20 0.44
MAOB P27338 1/20 0.42
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
PLA2G1B P04054 1/20 0.42
ATG4B Q9Y4P1 1/20 0.42
GAA P10253 1/20 0.42
RAB9A P51151 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
EGFR P00533 1/20 0.41
APP P05067 1/20 0.41
IDO1 P14902 1/20 0.40
NPC1 O15118 1/20 0.40
KDM4E B2RXH2 1/20 0.40
ALB P02768 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4343304 0.89 PDE7A (0.46) MAPTALDH1A1PDE7AMAOBMEN1
SCHEMBL4343414 0.88 EGFR (0.56) MAPTALDH1A1MAOBMEN1KMT2A
SCHEMBL4342064 0.87 EGFR (0.44) MAPTALDH1A1MAOBMEN1KMT2A
SCHEMBL4350107 0.87 ALDH3A1 (0.49) MAPTALDH1A1MAOBMEN1KMT2A
SCHEMBL4345719 0.86 NPC1 (0.48) MAPTALDH1A1PDE7AMEN1KMT2A
SCHEMBL4341720 0.85 NOX4 (0.58) MAPTALDH1A1MAOBMEN1KMT2A
SCHEMBL4346915 0.85 CYP3A4 (0.46) MAPTALDH1A1MAOBMEN1KMT2A
SCHEMBL4343309 0.85 NOX4 (0.45) MAPTALDH1A1MAOBMEN1KMT2A
SCHEMBL4350893 0.85 ALB (0.46) MAPTALDH1A1PDE7AMAOBMEN1
SCHEMBL4345804 0.83 MAPT (0.50) MAPTMAOBMEN1KMT2APLA2G1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP claimed
CN-1701061-A Novel compounds for inhibiting rotamase enzymes and uses thereof JERINI AG (DE) 2005-11-23 CN claimed
WO-2004030664-A2 NEW COMPOUNDS FOR THE INHIBITION OF UNDESIRED CELL PROLIFERATION AND USE THEREOF JERINI AG (DE) 2004-04-15 WO claimed
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF JERINI AG (DE) 2011-03-17 US disclosed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF NR1I3, NR1D1, NR1D2 MAPT 4439/4885ALDH1A1 2565/4885PDE7A 4703/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.